A 72-year-old woman with type 2 diabetes mellitus and chronic kidney disease (eGFR 28 mL/min/1.73m²) is hospitalized on day 5 post-abdominal hysterectomy. She develops fever (39.2°C), productive cough with purulent sputum, and hypoxia (SpO₂ 88% on room air). Chest X-ray shows bilateral lower-lobe infiltrates. She has received cefazolin (surgical prophylaxis) and has been on mechanical ventilation for 2 days post-operatively. Blood and sputum cultures are pending. What is the most likely causative organism and the most appropriate empirical antibiotic choice?

Explanation

## Clinical Diagnosis: Hospital-Acquired Pneumonia (HAP) **Key Point:** This patient has **Ventilator-Associated Pneumonia (VAP)**, a subset of HAP, defined as pneumonia occurring >48 hours after intubation in a mechanically ventilated patient. ## Risk Factors for HAP/VAP with Resistant Gram-Negatives | Risk Factor | Present? | Significance | |-------------|----------|---------------| | **Hospitalization >5 days** | Yes | Increases risk of resistant organisms | | **Mechanical ventilation >48 hrs** | Yes | VAP risk; *Pseudomonas* colonization | | **Recent surgery (abdominal)** | Yes | Aspiration risk; gram-negative flora | | **CKD (eGFR 28)** | Yes | Immunocompromise; altered drug clearance | | **Diabetes mellitus** | Yes | Impaired immune response | | **Bilateral infiltrates** | Yes | Suggests severe/progressive infection | ## Microbiology of HAP/VAP **High-Yield:** The most common causative organisms of HAP/VAP are **gram-negative bacilli**, particularly: - **Pseudomonas aeruginosa** (most common in VAP, especially after >5 days hospitalization) - *Acinetobacter baumannii* - *Enterobacteriaceae* (*Klebsiella*, *E. coli*) - *Staphylococcus aureus* (including MRSA) **Mnemonic for HAP/VAP pathogens: HACEK-PS** (Haemophilus, Acinetobacter, Citrobacter, Enterobacter, Klebsiella, Pseudomonas, Serratia) + *S. aureus*. ## Empirical Antibiotic Regimen for VAP with Risk Factors **Clinical Pearl:** VAP occurring after >5 days of hospitalization in a patient with risk factors (CKD, diabetes, recent surgery) requires coverage of **resistant gram-negative bacilli**, particularly *Pseudomonas aeruginosa*. ### Recommended Regimen: 1. **Piperacillin-tazobactam** (4.5 g IV Q6H) — beta-lactam/beta-lactamase inhibitor with excellent *Pseudomonas* coverage. - OR **Carbapenem** (meropenem or imipenem) if beta-lactam allergy. - OR **Cefepime** (4th-generation cephalosporin) if *Pseudomonas* susceptibility likely. 2. **Consider adding** vancomycin or linezolid if MRSA risk is high (prior MRSA colonization, vancomycin-resistant *Enterococcus* in unit). **Why piperacillin-tazobactam over cephalosporin?** - Broader spectrum against *Pseudomonas* and anaerobes (post-surgical aspiration risk). - Better lung penetration. - Guideline-recommended first-line for VAP with risk factors for *Pseudomonas*. [cite:Harrison 21e Ch 297; IDSA HAP/VAP Guidelines 2016]